Biochemical blood parameters in platinum fox females and males in ontogenesis by I. I. Okulova, Yu. A. Berezina, A. S. Syutkina, I. A. Plotnikov, O. Yu. Bespyatykh, I. A. Domsky

“…Results of biochemical tests of serum samples from platinum fox males and females of different age groups and comparative assessment thereof are presented. …”
Get full text

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma by Takayuki Ando, Ayumu Hosokawa, Hiroki Yoshita, Akira Ueda, Shinya Kajiura, Hiroshi Mihara, Sohachi Nanjo, Haruka Fujinami, Jun Nishikawa, Kohei Ogawa, Takahiko Nakajima, Johji Imura, Toshiro Sugiyama

“…Eight males and two females (median age, 67 years (range, 52–78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (n=7, 70%), cisplatin plus etoposide (n=2, 20%), and carboplatin plus etoposide (n=1, 10%) before amrubicin therapy. …”
Get full text

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy by İlker Selçuk, İpek Düzgüner, Sevda Baş, Taner Turan, Afra Alkan, Nurettin Boran, Mehmet Mutlu Meydanlı, Gökhan Tulunay

“… OBJECTIVE: To analyse the survival outcomes of women with ovarian carcinosarcoma according to platinum or doxorubicin based adjuvant chemotherapy protocols. …”
Get full text

Modern approaches to drug therapy of bladder cancer after first progression. by L. V. Bolotina, L. A. Koroleva

“…In case of impossibility of use of platinum derivatives treatment may be limited to the use of gemcitabine as monotherapy. …”
Get full text

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre by Maria João Santos, Filipa Ferro, Andrea Machado, Ana Sofia Vilariça, Direndra Hasmucrai, Paula Alves

“… First-line therapy for metastatic non-small-cell lung cancer without targetable mutations is platinum-based chemotherapy plus pembrolizumab if programmed death ligand 1 is < 50%. …”
Get full text

Efficacy and safety of super selective bronchial artery coil embolisation for haemoptysis: a single-centre retrospective observational study by Daijiro Kabata, Ayumi Shintani, Masanori Akira, Masahiko Hara, Hideo Ishikawa, Misaki Ryuge, Jun Takafuji, Mihoko Youmoto, Yukio Nagasaka, Kouji Yamamoto

“…Objectives Evidence on the safety and long-term efficacy of super selective bronchial artery embolisation (ssBAE) using platinum coils in patients with haemoptysis is insufficient. …”
Get full text

Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers by Zhihao Lu, Mingfei Geng, Yongtao Han, Jianzhong Cao, Jun Wang, Tianshu Liu, Xianglin Yuan, Xue Meng, Yanqiao Zhang, Rong Zhao, Lixin Wan, Enxiao Li, Wenran Wang, Zhijie Li, Danfeng Shi, Jing Qian, Si Shi, Fengshi Dong, Lin Shen

“…Results: Of 3,493 patients, 75.7% were men, the mean age was 64.1 years, and 75.0% had no family history of cancer. …”
Get full text

Real-World Treatment Patterns, Survival, and Costs for Ovarian Cancer in Canada: A Retrospective Cohort Study Using Provincial Administrative Data by Manjusha Hurry, Shazia Hassan, Soo Jin Seung, Ryan N. Walton, Ashlie Elnoursi, Jacob D. McGee

“…Current standard of care in Canada involves a combination of cytoreductive surgery and platinum-based chemotherapy. **Objective:** There are few studies reporting current OC costs. …”
Get full text

LATE-DEVONIAN SAKHARA DUNITE-CLINOPIROXENITE-GABBRO COMPLEX (EAST MAGNITOGORSK ZONE, SOUTH URALS): PETROLOGICAL-MINERALOGICAL FEATURES AND GEODYNAMIC SETTING by T.N. Surin

“…The geology and petrochemical-mineralogical features of the Sakhara dunite-clinopyroxenite-gabbro complex in the South Urals are characterized in the paper. Its late Frasnian age is substantiated. The composition of olivine, clinopyroxene and chromite in rocks of the complex are determined. …”
Get full text

Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database... by Sarah Waliany, Misako Nagasaka, Leah Park, Clara Lam, Zoe Jiang, Feng Lin, Joel W. Neal

“…Platinum‐based chemotherapy (45.5%) and immune checkpoint inhibitor (ICI) with chemotherapy (28.0%) were the most frequently used first‐line treatments. …”
Get full text

Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data by Bogdana Patachi, Kristian H. Jensen, Anita Gothelf, Mogens Bernsdorf, Jeppe Friborg, Claus A. Kristensen

“…There was no significant difference in survival times between patients ± 65 years of age or between patients with locoregional disease versus distant metastases. …”
Get full text

Primary Clear Cell Adenocarcinoma of the Cervix: A Clinical Analysis of 18 Cases without Exposure to Diethylstilbestrol by Dongying Wang, Chunhua Zhao, Li Fu, Yang Liu, Weiyang Zhang, Tianmin Xu

“…The median age was 53 years. The most common symptom was vaginal bleeding (66.7%, 12/18). …”
Get full text

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy by Shuai Wang, Yongsen Wang, Xuan Wu, Li Yang, Xiaoju Zhang

“…The median progression-free survival (mPFS) on first-line platinum plus etoposide after the conversion to SCLC was 3.0 months. …”
Get full text

Multimodal treatment with Neoadjuvant chemotherapy for eyelid and periocular sebaceous gland carcinoma: Long-term outcomes by Vijitha S. Vempuluru, Anshika Luthra, Vijay Anand Reddy Palkonda, Swathi Kaliki

“…Observations: Three patients of eSGC with 10-year follow-up were reviewed. The mean age at presentation of eSGC was 50 years (median, 50 years; range, 41–59 years). …”
Get full text

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence by Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

“…We observed no significant differences in age, sex, performance status (PS), liver metastasis, bone metastasis, or platinum‐based agent usage between the treatment cohorts. …”
Get full text

Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC by Evgenia Taranova, Marianne Aanerud, MD, PhD, Tarje O. Halvorsen, MD, PhD, Kristin T. Killingberg, MD, PhD, Marit Slaaen, MD, PhD, Bjørn H. Grønberg, MD, PhD

Get full text